Clinical trial
Study of Remodulin in Patients With Critical Limb Ischemia With No Planned…
NCT00060996 · United Therapeutics, Industry · Terminated
Key facts
| NCT number | NCT00060996 |
|---|---|
| Title | Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures |
| Official title | A Randomized Placebo-Controlled, 12-Week Multicenter Study of the Safety and Efficacy of Continuous or Daily Administration of Remodulin® (Treprostinil Sodium) Injection in Patients With CLI With No Planned Revascularization Procedures |
| Lead sponsor | United Therapeutics, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Critical Limb Ischemia, Peripheral Vascular Disease, Foot Ulcers, Rest Leg Pain |
| Intervention type | Drug |
| Interventions | Remodulin® (treprostinil sodium) Injection |
| Enrollment | 30 |
| Start date | Feb 1, 2003 |
| Primary completion | Sep 1, 2004 |
| Completion | Sep 1, 2004 |
| First posted | May 20, 2003 |
| Last update posted | Mar 7, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: